Evidence map›Paper›PMID 41088122›Full record

ArticleBMC endocrine disorders2025

Comparison of urinary prolactin and serum/urine prolactin ratio in hyperprolactinemic and macroprolactinemic patients.

Behnam Ein-Mozaffari, Akbar Aliasgharzadeh, Farzad Najafipour, Azam Moslemi, Mitra Niafar, Vahideh Sadra, Nasser Aghamohammadzadeh, Jalil Houshyar, Halimeh Amirazad

Abstract readComparative Study
In one paragraph

Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Behnam Ein-MozaffariEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Akbar AliasgharzadehEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Farzad NajafipourEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Azam MoslemiDepartment of Biostatistics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Mitra NiafarEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahideh SadraEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Nasser AghamohammadzadehEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Jalil HoushyarEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. jalilhoushyar@yahoo.com.
Halimeh AmirazadEndocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. f_Amirazad@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiologically, the monomeric form of prolactin is the most active. In measurement methods, all forms of prolactin are included in the assay; therefore, the presence of macroprolactin, causes a false increase in prolactin and misdiagnosis of hyperprolactinemia. It seems that if an alternative method can be used to check macroprolactin, it would be helpful. The study aims to investigate the urinary level of prolactin and its relationship with serum levels in cases of suspected macroprolactinemia and determine whether these tests can serve as a novel, non-invasive, accessible, and cost-effective tool for diagnosing macroprolactinemia.

methodsIn this cross-sectional study, patients who visited the Tabriz Imam Reza hospital clinic (2020–2021) with elevated prolactin levels. Prolactin and creatinine were checked in the urine and blood samples. After treating the serum with polyethylene glycol to precipitate macroprolactin, serum prolactin was measured again. The patients were divided into two groups. The first group, consisting of 19 individuals, with a recovery rate of more than 60%, formed the hyperprolactinemia group. The second group, comprising 36 individuals with a recovery rate of less than 60%, formed the macroprolactinemia group.

resultsThe participants in this study were 50 individuals, comprising 10 men and 40 women. The mean urinary prolactin levels in the hyperprolactinemia group are 43.27 ± 15.53, and in the macroprolactinemia group, they are 32.58 ± 16.27. This difference was statistically significant. The median ratio of urinary prolactin to urinary creatinine is 0.03 in the hyperprolactinemia group and 0.02 in the macroprolactinemia group (p<0.05). The median ratio of serum prolactin to urinary prolactin in the hyperprolactinemia group is 32.6, and in the macroprolactinemia group, it is 45.5 (p < 0.01).

conclusionFindings showed that the difference between urinary prolactin in true macroprolactinemic and hyperprolactinemic patients is significant, such that the amount of urinary prolactin in macroprolactinemic patients is less than in hyperprolactinemic patients, and the ratio of serum to urinary prolactin is higher. These parameters can be used to detect macroprolactin in cases of increased serum prolactin level, and this finding could provide a basis for the idea that these parameters can be used as an alternative to the PEG sedimentation test for diagnosing macroprolactin.

Indexed as

BiomarkersHyperprolactinemiaProlactinAdultCross-Sectional StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisYoung AdultBiomarkersProlactinprolactin, polymericCreatinineDiagnosisHyperprolactinemiaMacroprolactinemiaProlactin

Identifiers

PMID41088122
PMCPMC12522544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.